Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Anaphylaxis, including anaphylactic shock |
- Nasal
-
≥ 30 kg
-
2
mg/dose,
as required repeat once, administer is same nostril.
- Intramuscular
-
1 month
up to
18 years
-
Administration in hospital setting:
0.01
mg/kg/dose
Repeat 2 times at 15-minute intervals if necessary, then every 4 hours if necessary. Max: 0.5 mg/dose.
Self administration or administration by parents/caregivers:
7,5- 30 kg: 0.15 mg/dose (auto injector pen) 30-60 kg: 0.3 mg/dose (auto injector pen) ≥ 60 kg: 0.3-0.5 mg/dose (auto injector pen)
A second injection may be needed if the symptoms do not abate or are exacerbated after the first dose. The second injection can be administered after approximately 5-15 minutes.
- Subcutaneous
-
1 month
up to
18 years
-
0.01
mg/kg/dose
in 1
dose. Max: 0.5 mg/dose.
If necessary, repeat twice every 15 minutes, then every 4 hours..
|
| Resuscitation |
- Endotracheopulmonary
- Route of administration not applicable
-
1 month
up to
18 years
-
5
- 10
microg./kg/dose
in 1
dose once only.
- intra-osseous
-
1 month
up to
18 years
-
1:10,000 solution (0.1 mg/ml):
0.01
mg/kg/dose,
bolus.
- Corresponding to 0.1 ml/kg of 1:10.000 solution
- In case of asystole the following doses may be given: 0.1 mg/kg (corresponding to 0.1 ml/kg of 1:1000 solution)
- Repeat every 3-5 minutes if necessary
.
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Watch out for extravasation: central venous catheter. Watch out for renal and mesenteric vasoconstriction.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Adrenergic and dopaminergic agents |
|
|
|
C01CA07
|
|
|
|
C01CA04
|
|
|
|
C01CA26
|
|
|
|
C01CA02
|
|
|
|
C01CA17
|
|
|
|
C01CA24
|
|
|
|
C01CA03
|
|
|
|
C01CA06
|
| Phosphodiesterase inhibitors |
|
|
|
C01CE02
|
| Other cardiac stimulants |
|
|
|
C01CX08
|
References
-
Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
-
Mylan Healthcare B.V, SmPC Epipen Junior (RVG 32726) 10-11-2021, www.geneesmiddelinformatiebank.nl
-
Centrafarm, SmPC Adrenaline (RVG 50812) 14-06-2021, www.geneesmiddeleninformatiebank.nl
-
NVK, Richtlijn Reanimatie van het kind bij de geboorte, www.nvk.nl, 2014, http://www.nvk.nl/Kwaliteit/Richtlijnenoverzicht/Details/tabid/1558/articleType/ArticleView/articleId/765/Reanimatie-van-pasgeborenen.aspx#tab15
-
Brand, PLP et al, Werkboek Kinderlongziekten, VU Uitgeverij, 2001
-
Muraro A, et al, The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immun, Allergy, 2007, 62, 857-71
-
Cardona V., et al, World Allergy Organisation anaphylaxis guidelines: Summary, J ALLERGY CLIN IMMUNOL, 2020, 13, 100472
-
NVK, Richtlijn Astma bij Kinderen, 2013
-
Turner, NM, Leroy, P, Advanced Paediatric Life Support, de Nederlandse editie, Bohn, Stafleu van Loghum, 2015, 4e druk
-
Wyllie J. et al, European Resuscitation Council Guidelines for Resuscitation 2015 Section 7. Resuscitation and support of transition of babies at birth., Resuscitation, 2015, 95, 249-263
-
Sanofi, SmPC Suprarenin Injektionslösung (6196724.00.00/6091497.00.00), 08/2017
-
DR. Mann Pharma, SmPC Emerade 150/300/500 µg Injektionslösung in einem Fertigpen (86870.00.00), 12/2016
-
Infectopharm, SmPC Adrenalin 1:1000 Infektopharm Injektionslösung (3000341.00.00), 01/2015
-
Sanofi, SmPC Suprarenin® Ampullen, Durchstechflasche (6196724.00.00/6091497.00.00), 08/2017
-
Infectopharm, SmPC Infectokrupp Inhal 4mg/ml Lösung für einen Vernebler (52642.00.00), 01/2015
-
INFECTOPHARM, SmPC INFECTOKRUPP® Inhal (52642.00.00), 01/2015
-
Laboratoire Aguettant, SmPC Adrenalin 1:10.000 Aguettant, Injektionslösung in einer Fertigspritze (93835.00.00), 08/2016
-
MEDA Pharma, SmPC FASTJEKT® Junior (65312.00.00), 02/2017
-
MEDA Pharma, SmPC FASTJEKT® (13579.00.00), 02/2017
-
Dr. Gerhard Mann, SmPC Emerade 150/300/500 Mikrogramm Injektionslösung in einem Fertigpen (86870.00.00/86871.00.00/86872.00.00), 12/2016
-
EurimPharm, SmPC Epipen Junior Autoinjektor (88904.00.00), 02/2017
-
Barber CA, Wyckoff MH., Use and efficacy of endotracheal versus intravenous epinephrine during neonatal cardiopulmonary resuscitation in the delivery room., Pediatrics, 2006, 118(3), 1028-34
-
Baske K, et al., Epinephrine versus dopamine in neonatal septic shock: a double-blind randomized controlled trial, Eur J Pediatr, 2018, 177(9), 1335-42
-
Pellicer A, et al., Cardiovascular support for low birth weight infants and cerebral hemodynamics: a randomized, blinded, clinical trial., Pediatrics., 2005, 115(6), 1501-12
-
Valverde E, et al., Dopamine versus epinephrine for cardiovascular support in low birth weight infants: analysis of systemic effects and neonatal clinical outcomes., Pediatrics., 2006, 117(6), e1213-22
-
Aziz K, et al., Part 5: Neonatal Resuscitation: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, Circulation, 2020, 142(16_suppl_2), S524-s50
-
Halling C, et al., Efficacy of Intravenous and Endotracheal Epinephrine during Neonatal Cardiopulmonary Resuscitation in the Delivery Room., J Pediatr., 2017, 185, 232-6
-
Lee G, et al., Efficacy of Low-Dose Epinephrine Continuous Infusion in Neonatal Intensive Care Unit Patients., J Pediatr Pharmacol Ther., 2021, 26(1), 51-5
-
Muraro A, et al., Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology, Allergy, 2014, 69(8), 1026-45
-
Dr. Gerhard Mann, SmPC Emerade 150/300/500 Mikrogramm Injektionslösung in einem Fertigpen (86870.00.00/86871.00.00/86872.00.00), 12/2016
-
ALK-Abelló A/S, SmPC Eurneffy (EU/1/24/1846) Rev 4, 27/03/2025, www.geneesmiddelinformatiebank.nl
-
Aziz K, et al., Part 5: Neonatal Resuscitation: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, Circulation, 2020, 142(16_suppl_2), S524-s50
-
Aguettant, SPC Adrenaline (RVG 116588) nov 2020, www.cbg-meb.nl, https://www.geneesmiddeleninformatiebank.nl/smpc/h116588_smpc.pdf
Therapeutic Drug Monitoring
Overdose